BioCryst completes sale of European ORLADEYO business; receives $250M upfront

BIOCRYST PHARMACEUTICALS INC

Received $250M cash from sale of European ORLADEYO assets to Neopharmed Gentili; up to $14M in milestones.
Transaction valued at ~5.4x trailing 12-month European ORLADEYO sales (through June 2025).
Will use proceeds to retire $199M Pharmakon term loan, strengthening balance sheet.
Reaffirms FY2025 revenue guidance of $580M–$600M, expects upper half excluding European revenue.
European business was approximately breakeven; divestiture improves operating margin and focuses on U.S. core.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.